1. UnitedHealth Group's stock fell nearly 50% due to CEO resignation, guidance withdrawal, and legal issues, creating a potential buying opportunity; 2. The stock is oversold (RSI 15) and trading below key moving averages, signaling capitulation; 3. Attractive valuation (10x earnings), expected 2026 growth, and Stephen Hemsley's return as CEO suggest a rebound driven by buybacks and dividend growth.